Utility of routine screening for alpha-1 antitrypsin deficiency in patients with bronchiectasis

Luis Carreto, Meghan Morrison, Jackie Donovan, Simon Finch, Gan Liang Tan, Tom Fardon, Robert Wilson, Elisabeth Furrie, Michael Loebinger, James D. Chalmers (Lead / Corresponding author)

Research output: Contribution to journalArticle

14 Downloads (Pure)

Abstract

Alpha-1 antitrypsin deficiency (AATD) is a cause of bronchiectasis. Guidelines for bronchiectasis from the British Thoracic Society do not recommend to routinely test patients for AATD. In contrast, guidelines for AATD recommend routine screening. This contradiction, in part, results from the lack of data from large studies performing comprehensive screening. We screened 1600 patients with bronchiectasis at two centres in the UK from 2012 to 2016. In total, only eight individuals with AATD were identified representing 0.5% of the overall population. We conclude that routine screening for AATD in bronchiectasis in the UK has a low rate of detection. Further studies are required in different geographical regions, which may have a higher prevalence of AATD.

Original languageEnglish
Article number2019-214195
Number of pages2
JournalThorax
Early online date17 Apr 2020
DOIs
Publication statusE-pub ahead of print - 17 Apr 2020

Keywords

  • alpha1 antitrypsin deficiency
  • bronchiectasis
  • clinical epidemiology

Fingerprint Dive into the research topics of 'Utility of routine screening for alpha-1 antitrypsin deficiency in patients with bronchiectasis'. Together they form a unique fingerprint.

  • Cite this

    Carreto, L., Morrison, M., Donovan, J., Finch, S., Tan, G. L., Fardon, T., Wilson, R., Furrie, E., Loebinger, M., & Chalmers, J. D. (2020). Utility of routine screening for alpha-1 antitrypsin deficiency in patients with bronchiectasis. Thorax, [2019-214195]. https://doi.org/10.1136/thoraxjnl-2019-214195